@MeghUpdates India wants AI to help write government tenders. The useful question isn't whether that sounds futuristic. It's whether procurement gets faster without getting dumber. https://t.co/IWVFHIVfNc
#IndianAI#IndiaAI#MeitY#GovTech#AIPolicy
China’s new Order 818 path for cell and gene therapy is real. The catch: hospital translation, NMPA approval, and globally portable proof are not the same thing. Here’s the filter to use: https://t.co/uu6O5YDzC2 #ChinaBiotech#CellTherapy#Biotech
GSK's bepirovirsen data are real, but the useful question is not just whether 19% looks big. It is which hepatitis B patients qualified, what functional cure actually means, and whether this can scale in high-burden markets.
https://t.co/gp6zvgpIVo
#HepatitisB#GlobalHealth
Google is ending consumer Gemini CLI request serving on June 18. I broke down the migration risks that actually matter: plugins, skills, MCP config, auth, and whether your real workflow survives the move. https://t.co/mHIWw9S16g
#AntigravityCLI#GeminiCLI#GoogleAI
Akeso's ivonescimab win at ASCO is real. But HARMONi-6 is also a lesson in reading China-to-global biotech evidence: mechanism, comparator, geography, follow-up.
https://t.co/QrixJiE2sh
#Biotech#ChinaBiotech#ASCO2026#Oncology#LungCancer
India's AI GPU portal is live, but it is not free GPUs for everyone. I break down who qualifies, how pricing/subsidy works, and the approval catch builders should know. https://t.co/k5XuIIOI8l #IndiaAI#AIInfrastructure#IndianAI
@Lovable Do we even need lovable after this release?
/goal and /effort set to ultra build
with end goal minimal prompting
https://t.co/w3GrtC5KcA #Claude#AI#ClaudeCode
@adocomplete Try opus 4.8 with /goal and /effort set to ultra effort - single prompt to describe end goal and see the magic.
https://t.co/w3GrtC5KcA #Claude#AI#ClaudeCode
@kenbwork The useful part is the workflow shift: effort control, curated long context, cleaner tool loops, mid-task system messages, and dynamic workflows in Claude Code. https://t.co/w3GrtC5KcA
Claude Opus 4.8 is not just “better Claude.” The useful part is the workflow shift: effort control, curated long context, cleaner tool loops, mid-task system messages, and dynamic workflows in Claude Code. https://t.co/w3GrtC5KcA #Claude#AI#ClaudeCode
China’s Biotech Boom Reshapes Pharma, Sparks U.S. Industry Concerns
Merck announced two licensing deals with Chinese companies, and that really got people’s attention. So what’s going on?
WATCH TVR Best in Video ▶ https://t.co/lEk0phquhh
#ChinaBiotech#Merck#Pharma
ADC win is really a China biotech story: Kelun built sac-TMT, Merck is scaling it, and the caveats still matter.
https://t.co/DOydWfnVCu
#Biotech#ChinaBiotech#ADC#Oncology#ASCO2026
$MRK $
$DYN filed for accelerated approval in exon 51 Duchenne, but the real story is the evidence bar: surrogate dystrophin, FORZETTO, and what FDA still has to decide. https://t.co/AlB9W8B70O #Biotech#Duchenne#DMD#RareDisease#FDA
@bs2537 Published: Replimune's FDA Rejection
FDA rejected Replimune's RP1 again. The Boston biotech lesson is not just the setback. It is how single-arm oncology evidence can become a company-level risk. https://t.co/MXb70Tn5fJ
FDA rejected Replimune's RP1 again. The Boston biotech lesson is not just the setback. It is how single-arm oncology evidence can become a company-level risk. https://t.co/MXb70Tn5fJ #Biotech#BostonBiotech#FDA#Oncology#ClinicalTrials
https://t.co/MXb70Tn5fJ